Literature DB >> 2732721

Mechanism of immunity to influenza: maternal and passive neonatal protection following immunization of adult ferrets with a live vaccinia-influenza virus haemagglutinin recombinant but not with recombinants containing other influenza virus proteins.

K J Jakeman1, H Smith, C Sweet.   

Abstract

Neonatal ferrets are protected against infection with influenza virus by milk-derived anti-influenza virus IgG after suckling on an immune mother. Live vaccines protect better than killed vaccines despite their stimulation of lower maternal haemagglutination-inhibiting antibody levels. This suggests that antibody to virus proteins other than the haemagglutinin may also be involved. To investigate this, adult ferrets were immunized intradermally with live vaccinia-influenza virus recombinants each expressing one of the 10 influenza virus polypeptides. Adult ferrets immunized with a recombinant expressing the H3 haemagglutinin were completely protected, and also passively protected their offspring, against a live challenge with clone 7a of the reassortant influenza virus A/Puerto Rico/8/34-A/England/939/69 (H3N2), immunity being mediated by IgG antibody. However, ferrets immunized similarly with recombinants expressing the H1 haemagglutinin, neuraminidase (N1 or N2), polymerases (PB1, PB2 or PAC), matrix protein (M1 or M2), nucleoprotein (NP) or non-structural proteins (NS1 or NS2) were completely susceptible to the influenza virus.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2732721     DOI: 10.1099/0022-1317-70-6-1523

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  17 in total

Review 1.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

2.  Pathogenesis of avian influenza A (H5N1) viruses in ferrets.

Authors:  Lois A Zitzow; Thomas Rowe; Timothy Morken; Wun-Ju Shieh; Sherif Zaki; Jacqueline M Katz
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

3.  Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice.

Authors:  Leo L M Poon; Y H Connie Leung; John M Nicholls; Pin-Yu Perera; Jack H Lichy; Masafumi Yamamoto; Thomas A Waldmann; J S Malik Peiris; Liyanage P Perera
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 4.  Heterosubtypic immunity to influenza A virus: where do we stand?

Authors:  Kristie M Grebe; Jonathan W Yewdell; Jack R Bennink
Journal:  Microbes Infect       Date:  2008-07-09       Impact factor: 2.700

Review 5.  Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.

Authors:  Aseem Pandey; Neetu Singh; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Hum Vaccin       Date:  2010-02-24

6.  Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains.

Authors:  Y Okuno; K Matsumoto; Y Isegawa; S Ueda
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

7.  Vaccination with inactivated influenza A virus during pregnancy protects neonatal mice against lethal challenge by influenza A viruses representing three subtypes.

Authors:  I N Mbawuike; H R Six; T R Cate; R B Couch
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

8.  Efficacy of 2'-deoxy-2'-fluororibosides against influenza A and B viruses in ferrets.

Authors:  K J Jakeman; M Tisdale; S Russell; A Leone; C Sweet
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

9.  A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus.

Authors:  Alan G Goodman; Paul P Heinen; Susana Guerra; Aneesh Vijayan; Carlos Oscar S Sorzano; Carmen E Gomez; Mariano Esteban
Journal:  PLoS One       Date:  2011-10-05       Impact factor: 3.240

10.  A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection.

Authors:  Sankhiros Babapoor; Tobias Neef; Christian Mittelholzer; Theodore Girshick; Antonio Garmendia; Hongwei Shang; Mazhar I Khan; Peter Burkhard
Journal:  Influenza Res Treat       Date:  2012-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.